Immunovant Inc (IMVT)

Over the past six months, Immunovant's stock has increased by approximately 44%, with a share price of $24.61 as of April 7, 2026. Key events include the company reporting a net loss of $110.6 million for the third quarter ended December 31, 2025. Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) missed their primary endpoint, leading to Truist Securities reiterating a Hold rating, while Leerink Partners and Oppenheimer maintained Outperform ratings. Immunovant's Chief Legal Officer sold shares to cover tax withholding obligations related to vested restricted stock units.

Immunovant's demand seasonality is not directly comparable to consumer goods or services, as it is a clinical-stage biopharmaceutical company. Demand for its product candidates is primarily driven by the progression of clinical trials, regulatory approvals, and market adoption for specific autoimmune conditions. The prevalence of autoimmune diseases is generally not subject to seasonal fluctuations. The Tickeron Seasonality Score of 50 indicates that the company is fairly valued in the industry.

Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases, particularly those utilizing anti-FcRn technology. Its major product candidates include batoclimab (IMVT-1401), a monoclonal antibody designed to inhibit FcRn and reduce levels of pathogenic IgG antibodies, and IMVT-1402, a next-generation monoclonal antibody also inhibiting FcRn. Batoclimab is in clinical development for conditions like myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves' disease, and warm autoimmune hemolytic anemia. IMVT-1402 is being developed for multiple indications, including Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, and Sjögren's disease.

Immunovant, Inc. is headquartered in New York, New York, with a corporate office in Durham, North Carolina, and an office in Basel, Switzerland. Immunovant has subsidiaries including Immunovant Sciences Ltd. in Bermuda, IMVT Corporation in Delaware, Immunovant Holdings Limited in the United Kingdom, and Immunovant Sciences GmbH in Switzerland.

Immunovant's brand reputation is tied to its clinical trial progress and financial performance, and it is seen as a trailblazer in anti-FcRn technology. Analyst ratings show a consensus "Buy" rating. Positive clinical trial results for IMVT-1402 have highlighted promising results with a sustained reduction in TRAb levels during off-treatment periods. The Phase 3 trial results for Batoclimab in TED could negatively impact the perception of this specific asset. Regular corporate updates and financial results contribute to transparency and investor confidence.

Immunovant, Inc. is significantly owned by institutional shareholders (53.36%) and company insiders (58.30%). Roivant Sciences Ltd. is the largest individual shareholder, owning 55.68% of the company. Other major institutional and individual owners include Fmr LLC, Deep Track Capital LP, Vanguard Group Inc., BlackRock, Inc., Armistice Capital, Llc, Baker Bros. Advisors Lp, Morgan Stanley, State Street Corp, Rtw Investments, Lp, Two Seas Capital LP, and T. Rowe Price Investment Management Inc.